Xolair Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The xolair market research report is one of a series of new reports that provides xolair market statistics, including xolair industry global market size, regional shares, competitors with a xolair market share, detailed xolair market segments, market trends and opportunities, and any further data you may need to thrive in the xolair industry. This xolair market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast rising incidence of allergic diseases, increasing adoption of biologics in asthma treatment, expanding healthcare infrastructure in emerging markets, growing patient demand for targeted therapies, advancements in drug delivery methods. Major trends include the increased use of home-based biologic administration, rise in personalized medicine, growing focus on combination therapies, expansion of biologics in pediatric populations, and shift towards biosimilars in biologic treatments.

The growing prevalence of asthma is expected to drive the expansion of the Xolair market. Asthma is a chronic condition that leads to inflammation and narrowing of the airways, causing symptoms such as difficulty breathing, wheezing, and coughing. The rise in asthma cases can be linked to various factors including increased exposure to pollutants, changing weather patterns, rising temperatures, and higher population density. Xolair targets IgE antibodies, which helps reduce airway inflammation and prevents asthma attacks in patients with moderate to severe allergic asthma. According to data from the National Center for Health Statistics (NCHS) in December 2024, the prevalence of asthma among adults aged 18 and over in the U.S. increased slightly from 3.7% in 2022 to 3.8% in 2023. As asthma cases continue to rise, demand for Xolair is expected to increase.

A notable trend in the Xolair market is the focus on expanding its indications, particularly in allergy and immunology treatments, to address unmet medical needs in specialized areas. One such development is in IgE-mediated conditions, where immune responses triggered by IgE antibodies cause rapid allergic reactions, especially to food allergens. In February 2024, F. Hoffmann-La Roche Ltd. received FDA approval for Xolair (omalizumab) to reduce allergic reactions, including anaphylaxis, in patients aged 1 and older who suffer from IgE-mediated food allergies. This approval marks Xolair as the first FDA-approved treatment for reducing allergic reactions to multiple food allergens, although it is not intended for emergency use. Patients are still advised to avoid allergens, but this approval expands the treatment’s availability for those affected in the U.S.

In October 2023, Alvotech, a biotechnology company based in Luxembourg, entered into a licensing agreement with Kashiv Biosciences to develop AVT23, a biosimilar of Xolair (omalizumab). This collaboration focuses on creating a biosimilar version of Xolair, which is widely used to treat allergic asthma and chronic spontaneous urticaria. Kashiv Biosciences, a U.S.-based biopharmaceutical company, specializes in the production of Xolair biosimilars, and this partnership aims to make an affordable alternative treatment available to a larger patient population.

The key companies operating in the xolair market are F. Hoffmann-La Roche AG and Novartis AG.

North America was the largest region in the xolair market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in xolair report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the xolair market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Xolair (omalizumab) is a monoclonal antibody medication used to treat moderate to severe asthma, chronic idiopathic urticaria (hives), and nasal polyps. It works by targeting and inhibiting immunoglobulin E (IgE), a key antibody involved in allergic reactions, thereby reducing inflammation and improving symptom control. Xolair is typically prescribed for patients whose conditions are not adequately controlled with standard therapies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for xolair include asthma, chronic spontaneous urticaria (CSU), and nasal polyposis. In asthma, omalizumab is used to manage moderate to severe allergic asthma by reducing airway inflammation and preventing attacks in patients who are unresponsive to standard treatments. Distribution channels for Xolair include hospital pharmacies, retail pharmacies, and online pharmacies, and it is used by a wide range of patients, including adults, geriatrics, and pediatrics.

The xolair market consists of sales of subcutaneous injections with 150 mg/1.2 mL prefilled syringes and 75 mg/0.5 mL prefilled syringes. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.